Clinic and genetic predictors in response to erenumab

Background and purpose Erenumab (ERE) is the first anticalcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. A proportion of patients do not adequately respond to ERE. Methods Prospective multicenter study involving 110 migraine patients starting ERE 70 mg mo...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of neurology Vol. 29; no. 4; pp. 1209 - 1217
Main Authors:	Zecca, Chiara, Cargnin, Sarah, Schankin, Christoph, Giannantoni, Nadia Mariagrazia, Viana, Michele, Maraffi, Isabella, Riccitelli, Gianna Carla, Sihabdeen, Shairin, Terrazzino, Salvatore, Gobbi, Claudio
Format:	Journal Article
Language:	English
Published:	England John Wiley & Sons, Inc 01.04.2022 John Wiley and Sons Inc
Subjects:	Alleles anti‐CGRP antibodies Calcitonin Confidence intervals Demographics Demography erenumab Genetic diversity Genetic variance Headache Impact tests Migraine Monoclonal antibodies Original Patients Polymerase chain reaction predictors Receptor activity modifying proteins Receptors Regression analysis Regression models Statistical analysis treatment response predictors anti-CGRP antibodies erenumab treatment response
ISSN:	1351-5101, 1468-1331, 1468-1331
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!